Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

Reynes, Jacques; Lawal, Adebayo; Pulido, Federico; Soto-Malave, Ruth; Gathe, Joseph; Tian, Min; Fredrick, Linda; Podsadecki, Thomas; M. Nilius, Angela

doi:10.1310/hct1205-255

Public

Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

Published in HIV Clinical Trials • Oct 1, 2011

Authors:

Jacques Reynes

Adebayo Lawal

Federico Pulido

Abstract

PURPOSE: Current antiretroviral regimens recommended for treatment-naïve patients include 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). The purpose of this study is to evaluate whether a new NRTI-sparing regimen may provide an alternative for persons for whom traditional regimens...

Subject

Raltegravir

Medicine

Emtricitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!